title: Overexpression of the platelet P2X1 ion channel in transgenic mice generates a novel prothrombotic phenotype.
abstract: We have generated transgenic mice overexpressing the human P2X(1) ion channel in the megakaryocytic cell lineage. Platelets from transgenic mice exhibited a gain of P2X(1) ionotropic activity as determined by more prominent P2X(1)-mediated Ca(2+) influx and platelet shape change. P2X(1) overexpression enhanced platelet secretion and aggregation evoked by low doses of collagen, convulxin, or the thromboxane A(2) mimetic U46619. In contrast, transgenic platelet responses to adenosine diphosphate (ADP) or thrombin were normal. Perfusing whole blood from transgenic mice over collagen fibers at a shear rate of 1000 seconds(-1) resulted in increased P2X(1)-dependent aggregate formation and phosphatidylserine exposure. Platelet hyperreactivity to collagen was correlated with up-regulated extracellular signal-regulated kinase 2 (ERK2) phosphorylation. Accordingly, the MEK1/2 inhibitor U0126 potently inhibited the collagen-induced aggregation of transgenic platelets when stirred or when perfused over a collagen surface. In a viscometer, shear stress caused potent aggregation of transgenic platelets under conditions in which wild-type platelets did not aggregate. In an in vivo model of thromboembolism consisting of intravenous injection of a low dose of collagen plus epinephrine, transgenic mice died more readily than wild-type mice. Preinjection of U0126 not only fully protected transgenic mice against thrombosis, it also enhanced the survival of wild-type mice injected with a higher collagen dose. Hence, the platelet P2X(1) ion channel plays a role in hemostasis and thrombosis through its participation in collagen-, thromboxane A(2)-, and shear stress-triggered platelet responses. Activation of the ERK2 pathway is instrumental in these processes.
authors.affiliation: Center for Molecular and Vascular Biology, University of Leuven, Belgium.
authors.forename: Cécile
authors.initials: C
authors.lastname: Oury
authors.forename: Marijke J E
authors.initials: MJ
authors.lastname: Kuijpers
authors.forename: Emese
authors.initials: E
authors.lastname: Toth-Zsamboki
authors.forename: Arnaud
authors.initials: A
authors.lastname: Bonnefoy
authors.forename: Sophie
authors.initials: S
authors.lastname: Danloy
authors.forename: Ingrid
authors.initials: I
authors.lastname: Vreys
authors.forename: Marion A H
authors.initials: MA
authors.lastname: Feijge
authors.forename: Rita
authors.initials: R
authors.lastname: De Vos
authors.forename: Jos
authors.initials: J
authors.lastname: Vermylen
authors.forename: Johan W M
authors.initials: JW
authors.lastname: Heemskerk
authors.forename: Marc F
authors.initials: MF
authors.lastname: Hoylaerts
mesh_terms: D000244:Adenosine Diphosphate / Q000494:pharmacology; D000818:Animals; D001772:Blood Cell Count; D001792:Blood Platelets / Q000166:cytology / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D048429:Cell Size; D004906:Erythrocyte Count; D006801:Humans; D007473:Ion Channels / Q000235:genetics / Q000502:physiology; D007700:Kinetics; D008533:Megakaryocytes / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic; D010641:Phenotype; D010976:Platelet Count; D018048:Receptors, Purinergic P2 / Q000235:genetics*; D058469:Receptors, Purinergic P2X; D013917:Thrombin / Q000494:pharmacology; D013927:Thrombosis / Q000235:genetics*
chemical_list: D007473:Ion Channels; D018048:Receptors, Purinergic P2; D058469:Receptors, Purinergic P2X; D000244:Adenosine Diphosphate; D013917:Thrombin